ReceptorsChimeric antigen receptor T cellsProteinsType of immunotherapyAntibodiesCenter for Cellular ImmunotherapiesReprogrammed-antigen preseClinicalCancer-fighting immunoTherapiesCD19ImmunologyCellsTypes of immunotherapyCellularCell immunotherapyBCMADendriticTumors2023MelanomaInducesVaccineAutoimmune DiseasesTherapyAllergenMoleculeImmune ToleranceApproachesPatientsRecognize
Receptors6
- Chimeric antigen receptors (CARs) are synthetic proteins expressed on the surface of T cells. (medscape.com)
- Adoptive transfer of T cells transduced with tumor-reactive Chimeric Antigen Receptors (CARs) is a promising strategy for cancer immunotherapy. (biomedcentral.com)
- These proteins are called c himeric antigen receptors (CARs). (ohsu.edu)
- A patient's NK (natural killer) cells - like T cells - can be modified to develop chimeric antigen receptors (CARs) that target cancer cells. (ohsu.edu)
- In this process, T cells are collected from patients via leukapheresis and then re-engineered to express chimeric antigen receptors. (medscape.com)
- Chimeric antigen receptors (CAR) recognize specific proteins on the surface of tumor cells. (msdmanuals.com)
Chimeric antigen receptor T cells6
- It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). (nih.gov)
- Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×10(6) to 1.2×10(7) CTL019 cells per kilogram of body weight. (nih.gov)
- In addition, the chimeric antigen receptor T cells were observed in the cerebrospinal fluid (CSF), where they persisted at high levels for at least 6 months. (nih.gov)
- cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. (nih.gov)
- Chimeric antigen receptor T cells - CAR-T cells, for short - are an innovative development in the field of oncology, contributing to the emergence of immunotherapy as the fourth pillar of cancer treatment , particularly for patients with late-stage or rare forms of cancer. (corning.com)
- Chimeric antigen receptor T cells for gamma-delta T cell malignancies. (ucl.ac.uk)
Proteins4
- MHC-I and MHC-II proteins are key components of the antigen presentation machinery responsible for neoantigen presentation to CD8 + and CD4 + T lymphocytes, respectively. (portlandpress.com)
- Monoclonal antibodies are lab-generated proteins that target specific tumor antigens (substances that the immune system sees as being foreign or dangerous). (cancercare.org)
- Bispecific antibodies are lab-generated proteins that target specific tumor antigens (as do monoclonal antibodies) but also bind proteins on the surface of T-cells. (cancercare.org)
- However, cDC1 can be compromised in cancer patients and some cancer cells lack these antigen-presenting proteins on their surface, impacting immunotherapy response. (lu.se)
Type of immunotherapy4
- This type of immunotherapy is currently used to treat melanoma. (medlineplus.gov)
- In March 2021, we became the first center in the world to use NK therapy, a type of immunotherapy, in a patient with advanced lymphoma. (ohsu.edu)
- OHSU's Dr. Richard Maziarz leads research on CAR T-cell therapy, a type of immunotherapy that's bringing powerful new options to children and adults with blood cancer. (ohsu.edu)
- Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses a person's own T-cells (a type of white blood cell) to treat certain blood cancers. (cancercare.org)
Antibodies3
- Antibodies against proliferating cell nuclear antigen (PCNA) or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. (wikipedia.org)
- CDR2 antigen and Yo antibodies. (uib.no)
- Administration of exogenous antibodies constitutes passive humoral immunotherapy. (msdmanuals.com)
Center for Cellular Immunotherapies2
- Both achieved full remission-Olson was cancer-free within weeks-and their cancer did not return, leading senior study author Carl June, MD, director of the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, to say they were cured. (poz.com)
- Then, the immune system reboots, and now it's working, whereas before it was messed up," said Carl June, MD , who directs the Center for Cellular Immunotherapies at the at the University of Pennsylvania's Perelman School of Medicine. (medscape.com)
Reprogrammed-antigen prese1
- Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-antigen presenting cells (TR-APCs). (lu.se)
Clinical10
- We studied the relationship between KIR-human leukocyte antigen (HLA) combinations and the clinical outcomes of patients with Ebola virus disease (EVD). (cdc.gov)
- We shed light on the importance of both preclinical and clinical vaccine studies demonstrating that tolerance and autoimmunity (presumed to preclude this class of antigens from vaccine development) can be overcome and do not present the obstacle that might have been expected. (nih.gov)
- Selecta Biosciences , a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. (centerwatch.com)
- In addition, Selecta is eligible to receive several pre-clinical, clinical, regulatory and sales milestones totaling $300 million per allergen indication for up to three immunotherapy candidates contemplated by this collaboration. (centerwatch.com)
- It outlines current approaches employed at the preclinical and clinical trial interface towards reversing these processes in order to improve response to immunotherapy and survival outcomes for patients with cancer. (portlandpress.com)
- We have many clinical trials to test promising new immunotherapies, and more on the way. (ohsu.edu)
- The cancer research network based at OHSU is leading the first federally funded clinical trial of immunotherapy for rare cancers. (ohsu.edu)
- A high-throughput system, like the one utilized in the Corning study, could provide additional insight into antigen targets before the clinical stage. (corning.com)
- Among tumor immunotherapies, neoantigen vaccines are in early human clinical trials and have demonstrated substantial efficiency. (wjgnet.com)
- This code applies to clinical situations in which multiple injections of antigens are administered over a few hours at 30- to 120-minute intervals. (medscape.com)
Cancer-fighting immuno1
- Here are examples of cancer-fighting immunotherapies available at the Knight Cancer Institute. (ohsu.edu)
Therapies4
- Moreover, in the context of immunotherapy, immunological biomarkers could serve as indicators of immunological competence and therefore susceptibility to immune-based therapies. (biomedcentral.com)
- B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. (myeloma.ca)
- Finding the right balance is a key consideration in cancer immunotherapy approaches such as combination therapies and precision medicine. (genengnews.com)
- B-cell targeted therapies have been around since the early 2000s with drugs like rituximab , a monoclonal antibody medication that targets CD20, an antigen expressed on the surface of B cells. (medscape.com)
CD196
- One example is adoptive cell therapy with T cells that were genetically modified with gamma-retroviral and lentiviral (LV) delivery vectors to express a CD19-specific chimeric antigen receptor (CAR) for cancer treatment. (uni-wuerzburg.de)
- The aAPC were genetically modified to present the target antigen CD19 along with no co-stimulation, or co-stimulation via CD86, CD137L, or both molecules. (bmj.com)
- Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). (nih.gov)
- While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. (lls.org)
- Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (ucl.ac.uk)
- The CAR T cells currently available target another surface antigen, CD19, and are a much more potent therapy. (medscape.com)
Immunology4
- We are very pleased that Sanofi, a global leader in vaccines and immunology, is entering into a partnership with Selecta to develop and commercialize products from our immunotherapy platform," said Werner Cautreels, PhD, president and CEO of Selecta. (centerwatch.com)
- Cancer Immunology and Immunotherapy. (uib.no)
- Rosa et al, Science Immunology 2022 ) and has shown recently that the same combination of factors can reprogram tumor cells into antigen presenting cells (Zimmermannova et al, In revision). (lu.se)
- Documented knowledge in tumor immunology, with practical experience in in-vivo evaluation of cancer immunotherapies using mouse syngeneic mouse models. (lu.se)
Cells39
- Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. (lu.se)
- Non-virally transformed T cells, induced to genomically integrate CAR by Sleeping Beauty transposase, were numerically expanded on artificial antigen presenting cells (aAPC) derived from K562. (bmj.com)
- Proliferating cell nuclear antigen (PCNA) is a DNA clamp that acts as a processivity factor for DNA polymerase δ in eukaryotic cells and is essential for replication. (wikipedia.org)
- PCNA was originally identified as an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of the cell cycle. (wikipedia.org)
- Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. (nih.gov)
- When these cells die, they release substances called antigens. (medlineplus.gov)
- These antigens tell the immune system to target and kill other cancer cells in the body. (medlineplus.gov)
- We aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes (CTLs). (biomedcentral.com)
- Efficient antigen presentation by antigen presenting cells (APCs) is critical for inducing T-cell mediated immunity in vivo [ 1 , 2 ]. (biomedcentral.com)
- Dendritic cells (DCs), activated macrophages, and activated B cells are all capable of presenting antigen peptides. (biomedcentral.com)
- Antigen-specific CD40L-activated B cells may efficiently endocytose and present antigens, such as protein, RNA, and cDNA, to prime primary T cells and boost robust memory T-cell responses [ 9 ]. (biomedcentral.com)
- However, little is known whether CD40L-activated B cells may present HBV antigen to T cells. (biomedcentral.com)
- A key mechanism of immune evasion deployed by tumour cells is to reduce neoantigen presentation through down-regulation of the antigen presentation machinery. (portlandpress.com)
- Their expression in tumour cells is modulated by a complex interplay of genomic, transcriptomic and post translational factors involving multiple intracellular antigen processing pathways. (portlandpress.com)
- Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. (ox.ac.uk)
- Subsequent adoptive transfer of virus activated spleen cells into RIP(GP x Tag2) mice further prolonged survival (168 +/- 11 d), demonstrating continued expression of the LCMV-GP tumor antigen and MHC class I. The data show that the tumor did not spontaneously induce or maintain an activated CTL response, revealing a profound lack of immunogenicity in vivo. (ox.ac.uk)
- B). Upon antigen activation, CD8+ T cells upregulate the IL-10 receptor and IL-10. (baxkyardgardener.com)
- Autocrine and therapeutic IL-10 increases anti-apoptotic signals and IFN?in those antigen experienced CD8+ T cells. (baxkyardgardener.com)
- C). Pegilodecakin induces directly IFN, Granzyme and FasL expression in antigen activated CD8+ T cells, facilitating the upregulation of MHC I around the tumor cell and induction of tumor cell killing. (baxkyardgardener.com)
- Immunotherapies change how the immune system works so it can find and destroy cancer cells. (ohsu.edu)
- CAR-T cells are made using a patient's T-cells , which are harvested through apheresis and built up in a laboratory through the addition of a chimeric antigen receptor. (corning.com)
- When the CAR-T cells return to the patient's body, they target cell-surface antigens expressed on tumor cells. (corning.com)
- One challenge in using CAR-T immunotherapy to treat solid tumors is delivering the CAR-T cells directly to the tumor. (corning.com)
- For some people with cancer, immunotherapy drugs called checkpoint inhibitors , which take the brakes off the immune system and allow it to attack cancer cells, have been a game changer. (mskcc.org)
- In a laboratory, the T-cells are genetically re-engineered by adding a chimeric antigen receptor to their surface. (cancercare.org)
- Chimeric antigen receptor T-cell therapy-better known as CAR-T-modifies a patient's own T cells to enable them to better fight cancer. (poz.com)
- In passive cellular immunotherapy, specific effector cells are directly infused and are not induced within the patient. (msdmanuals.com)
- Passive cellular immunotherapy references A number of immunologic interventions, both passive and active, can be directed against tumor cells. (msdmanuals.com)
- In passive cellular immunotherapy, specific effector cells. (msdmanuals.com)
- Tumor Antigens Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
- Concomitant use of interferon enhances the expression of major histocompatibility complex (MHC) antigens and TAAs on tumor cells, thereby augmenting the killing of tumor cells by the infused effector cells. (msdmanuals.com)
- COVID-19: Attacks Immune Cells and Interferences With Antigen Presentation Through MHC-Like Decoy System. (cdc.gov)
- Immunotherapy can fail in patients with cancer when certain cancer cells can hide from the immune system. (lu.se)
- By using direct reprogramming strategies, I could induce the expression of tumor antigens on the surface of cancer cells, making them visible to the immune system again. (lu.se)
- We focused particularly on harnessing reprogramming, or direct cellular reprogramming, to induce antigen presentation in cancer cells. (lu.se)
- when it comes to cancer they are critical as they present tumor antigens to the killer cells of the immune system and orchestrate the anti-tumor immune response. (lu.se)
- Direct reprogramming strategies with cDC1-specific factors can induce antigen-presentation in cancer cells, making cancer cells visible to the immune system and easier to fight. (lu.se)
- Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy. (lu.se)
- This project will aim to test a cancer immunotherapy approach based on in-vivo dendritic cell reprogramming of tumor cells to reinstate anti-tumor immunity. (lu.se)
Types of immunotherapy3
- There are several types of immunotherapy for cancer. (medlineplus.gov)
- The side effects for different types of immunotherapy for cancer differ by the type of treatment. (medlineplus.gov)
- There are many types of immunotherapy. (ohsu.edu)
Cellular1
- Chimeric antigen receptor (CAR) T-cell therapy has offered a novel approach to treating hematologic cancers since 2017, but there are early signs that these cellular immunotherapies could be repurposed for B-cell mediated autoimmune diseases. (medscape.com)
Cell immunotherapy1
- CAR T cell immunotherapy for human cancer. (msdmanuals.com)
BCMA1
- To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-BCMA and/or anti-GPRC5D CAR T/TCE therapy. (myeloma.ca)
Dendritic1
- Experience in dendritic cell biology and antigen presentation mechanisms is a merit, T cell biology is also attractive. (lu.se)
Tumors1
- The simian virus 40 T antigen (Tag) expressed under the control of the rat insulin promoter (RIP) induced pancreatic beta-cell tumors producing insulin, causing progressive hypoglycemia. (ox.ac.uk)
20231
- Journal of immunotherapy (Hagerstown, Md. : 1997) 2023 0 0. (cdc.gov)
Melanoma3
- Further investigations of melanoma-associated antigens present in Melacine and presented by HLA-A2 and HLA-Cw3 may be warranted. (northwestern.edu)
- Healthy humans develop spontaneous CD8+ T cell responses to melanoma associated antigens (MA) expressed by normal melanocytes. (mdpi.com)
- Immunotherapies have greatly increased survival times in people with aggressive cancers such as advanced melanoma and advanced lung cancer. (ohsu.edu)
Induces1
- IFN- induces antigen presentation and the development of CD8+ T cell immunity. (baxkyardgardener.com)
Vaccine3
- Overexpressed tumor-self antigens represent the largest group of candidate vaccine targets. (nih.gov)
- This review considers this subset of self antigens by highlighting vaccine efforts for some of the better known members and focusing on TPD52, a new promising vaccine target. (nih.gov)
- The products resulting from this collaboration will leverage Selecta's proprietary Synthetic Vaccine Particle (SVP) platform which is capable of engineering nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens. (centerwatch.com)
Autoimmune Diseases1
- In addition, the data suggest that the risk for induction of chronic autoimmune diseases is limited, which may encourage immunotherapy against antigens selectively but not exclusively expressed by the tumor. (ox.ac.uk)
Therapy6
- Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing treatment modality. (medscape.com)
- The potential of this class of antigens for broad application is considered, possibly in the context of low tumor burden or adjuvant therapy, as is the need to understand mechanisms of tolerance that are relatively understudied. (nih.gov)
- Chimeric antigen receptor T-cell therapy has recently emerged as a potent and potentially curative form of immunotherapy in hematological malignancies. (mayoclinic.org)
- Testing CAR-T therapy on 3D spheroids can help scientists pick the proper antigen targets. (corning.com)
- Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. (lls.org)
- Research has intensified to understand ERV protein function and their role as tumor antigens and targets for cancer (immune) therapy. (frontiersin.org)
Allergen4
- Sanofi obtains an exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies each to a specific food or aeroallergen. (centerwatch.com)
- Novel adjuvants and antigen-delivery systems with immunomodulatory properties that shift the allergenic Th2 response towards a Th1 or regulatory T cell response are desired for allergen-specific immunotherapy. (lu.se)
- Thus, gamma-PGA NPs are promising as sophisticated adjuvants and allergen-delivery systems in allergen-specific immunotherapy. (lu.se)
- A way to circumvent these problems is to pursue an accelerated allergen immunotherapy schedule with either the cluster or the rush approach, techniques that involve giving patients successive doses of allergy injections on the same day. (medscape.com)
Molecule1
- Any molecule capable of being recognized by the immune system is considered an antigen. (msdmanuals.com)
Immune Tolerance1
- Selecta's SVP technology can restore balance to dysregulated immune systems by producing immune tolerance to specific antigens. (centerwatch.com)
Approaches1
- Dale Schenk of Elan led off an immunotherapy symposium by noting second-generation approaches his company is currently exploring. (alzforum.org)
Patients5
- The Knight Cancer Institute was among the first in the nation to treat patients who have advanced prostate cancer with the immunotherapy medication Provenge. (ohsu.edu)
- Our initial investment in CAR T in the 1990's, when CAR T, and indeed immunotherapy to treat cancer was in its infancy, has turned into a game-changing therapeutic giving new hope to patients with limited treatment options and often very poor prognoses. (lls.org)
- [10] It is less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient. (wikipedia.org)
- Oral immunotherapy is an option for a selected group of patients whose major symptoms are restricted to one season. (medscape.com)
- Those patients might be recaptured with a less cumbersome approach to immunotherapy. (medscape.com)
Recognize2
- The purpose of cancer-targeting immunotherapy is to modify the immune system to recognize that the cancer is foreign to the body and needs to be attacked. (cancercare.org)
- Moreover, the genetic engineering of macrophages with chimeric antigen receptor (CAR) allows them to recognize tumor antigens and perform tumor cell-specific phagocytosis. (springer.com)